Literature DB >> 20346943

Transcriptome analysis of a tau overexpression model in rats implicates an early pro-inflammatory response.

David B Wang1, Robert D Dayton, Richard M Zweig, Ronald L Klein.   

Abstract

Neurofibrillary tangles comprised of the microtubule-associated protein tau are pathological features of Alzheimer's disease and several other neurodegenerative diseases, such as progressive supranuclear palsy. We previously overexpressed tau in the substantia nigra of rats and mimicked some of the neurodegenerative sequelae that occur in humans such as tangle formation, loss of dopamine neurons, and microgliosis. To study molecular changes involved in the tau-induced disease state, we used DNA microarrays at an early stage of the disease process. A range of adeno-associated virus (AAV9) vector doses for tau were injected in groups of rats with a survival interval of 2 weeks. Specific decreases in messages for dopamine-related genes validated the technique with respect to the dopaminergic cell loss observed. Of the mRNAs upregulated, there was a dose-dependent effect on multiple genes involved in immune response such as chemokines, interferon-inducible genes and leukocyte markers, only in the tau vector groups and not in dose-matched controls of either transgene-less empty vector or control green fluorescent protein vector. Histological staining for dopamine neurons and microglia matched the loss of dopaminergic markers and upregulation of immune response mRNAs in the microarray data, respectively. RT-PCR for selected markers confirmed the microarray results, with similar changes found by either technique. The mRNA data correlate well with previous findings, and underscore microgliosis and immune response in the degenerative process following tau overexpression. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20346943      PMCID: PMC2906769          DOI: 10.1016/j.expneurol.2010.03.011

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  35 in total

1.  The human HERC family of ubiquitin ligases: novel members, genomic organization, expression profiling, and evolutionary aspects.

Authors:  Karin Hochrainer; Herbert Mayer; Ulrike Baranyi; Berndr Binder; Joachim Lipp; Renate Kroismayr
Journal:  Genomics       Date:  2005-02       Impact factor: 5.736

Review 2.  Frontotemporal lobar degeneration: current concepts in the light of recent advances.

Authors:  Samir Kumar-Singh; Christine Van Broeckhoven
Journal:  Brain Pathol       Date:  2007-01       Impact factor: 6.508

Review 3.  Positive and negative MHC class I recognition by rat NK cells.

Authors:  B Rolstad; J T Vaage; C Naper; D Lambracht; K Wonigeit; E Joly; G W Butcher
Journal:  Immunol Rev       Date:  1997-02       Impact factor: 12.988

4.  Tau pathology in a family with dementia and a P301L mutation in tau.

Authors:  S S Mirra; J R Murrell; M Gearing; M G Spillantini; M Goedert; R A Crowther; A I Levey; R Jones; J Green; J M Shoffner; B H Wainer; M L Schmidt; J Q Trojanowski; B Ghetti
Journal:  J Neuropathol Exp Neurol       Date:  1999-04       Impact factor: 3.685

5.  Improved detection of substantia nigra pathology in Alzheimer's disease.

Authors:  Julie A Schneider; Julia L Bienias; David W Gilley; David E Kvarnberg; Elliott J Mufson; David A Bennett
Journal:  J Histochem Cytochem       Date:  2002-01       Impact factor: 2.479

Review 6.  Disease modifying therapy for AD?

Authors:  Todd E Golde
Journal:  J Neurochem       Date:  2006-11       Impact factor: 5.372

7.  An R5L tau mutation in a subject with a progressive supranuclear palsy phenotype.

Authors:  Parvoneh Poorkaj; Nancy A Muma; Victoria Zhukareva; Elizabeth J Cochran; Kathleen M Shannon; Howard Hurtig; William C Koller; Thomas D Bird; John Q Trojanowski; Virginia M-Y Lee; Gerard D Schellenberg
Journal:  Ann Neurol       Date:  2002-10       Impact factor: 10.422

8.  Molecular chaperone-mediated tau protein metabolism counteracts the formation of granular tau oligomers in human brain.

Authors:  N Sahara; S Maeda; Y Yoshiike; T Mizoroki; S Yamashita; M Murayama; J-M Park; Y Saito; S Murayama; A Takashima
Journal:  J Neurosci Res       Date:  2007-11-01       Impact factor: 4.164

9.  Pronounced microgliosis and neurodegeneration in aged rats after tau gene transfer.

Authors:  Ronald L Klein; Robert D Dayton; Cynthia G Diaczynsky; David B Wang
Journal:  Neurobiol Aging       Date:  2009-01-19       Impact factor: 4.673

10.  The role of tau in neurodegeneration.

Authors:  Tania F Gendron; Leonard Petrucelli
Journal:  Mol Neurodegener       Date:  2009-03-11       Impact factor: 14.195

View more
  6 in total

1.  Dendritic degeneration, neurovascular defects, and inflammation precede neuronal loss in a mouse model for tau-mediated neurodegeneration.

Authors:  Tomasz Jaworski; Benoit Lechat; David Demedts; Lies Gielis; Herman Devijver; Peter Borghgraef; Hans Duimel; Fons Verheyen; Sebastian Kügler; Fred Van Leuven
Journal:  Am J Pathol       Date:  2011-08-10       Impact factor: 4.307

Review 2.  Role of pro-inflammatory cytokines released from microglia in Alzheimer's disease.

Authors:  Wen-Ying Wang; Meng-Shan Tan; Jin-Tai Yu; Lan Tan
Journal:  Ann Transl Med       Date:  2015-06

3.  Gene Therapy Models of Alzheimer's Disease and Other Dementias.

Authors:  Benjamin Combs; Andrew Kneynsberg; Nicholas M Kanaan
Journal:  Methods Mol Biol       Date:  2016

4.  Adult-onset focal expression of mutated human tau in the hippocampus impairs spatial working memory of rats.

Authors:  Martina L Mustroph; Michael A King; Ronald L Klein; Julio J Ramirez
Journal:  Behav Brain Res       Date:  2012-04-25       Impact factor: 3.332

Review 5.  Tau and neuroinflammation: What impact for Alzheimer's Disease and Tauopathies?

Authors:  Cyril Laurent; Luc Buée; David Blum
Journal:  Biomed J       Date:  2018-03-20       Impact factor: 4.910

6.  Microglial Heterogeneity and Its Potential Role in Driving Phenotypic Diversity of Alzheimer's Disease.

Authors:  Stefano Sorrentino; Roberto Ascari; Emanuela Maderna; Marcella Catania; Bernardino Ghetti; Fabrizio Tagliavini; Giorgio Giaccone; Giuseppe Di Fede
Journal:  Int J Mol Sci       Date:  2021-03-09       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.